GlaxoSmithKline transfers rare disease gene therapies to Orchard Therapeutics

GlaxoSmithKline has signed a strategic agreement to transfer its portfolio of approved and investigational rare disease gene therapies to Orchard Therapeutics.

This decision has been taken as part of a strategic realignment on GlaxoSmithKline's part, with the company set to continue to invest in the development of platform capabilities in cell and gene therapies, with a focus on oncology.

Orchard, meanwhile, will be able to reinforce its own position as a global leader in gene therapy for rare diseases, while the continued development of the programmes in question and patient access to these therapies will be secured.

Under the terms of the deal, GlaxoSmithKline will receive a 19.9 percent stake in Orchard Therapeutics, along with a seat on the company's board. The partners will exchange manufacturing, technical and commercial insights to ensure the success of the partnership.

John Lepore, senior vice-president of GlaxoSmithKline's research and development pipeline, said: "We're confident that this agreement combined with the ongoing relationship between the two companies will support the progression of these valuable programmes to enable them to benefit patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.